Table 2_Continuing immune checkpoint inhibitors beyond progression versus switching to non

A real-world study of 169 patients with advanced gastric or gastroesophageal junction cancer who progressed after first-line immuno-chemotherapy. The dataset compares survival outcomes for patients who continued immune checkpoint inhibitors beyond progression versus those who switched to non-immunotherapy regimens. The research was authored by Guangxi Wang and shared on figshare in June 2026.

Use Cases

• Compare progression-free survival between treatment continuation and switch strategies based on the reported median PFS values.
• Analyze overall survival benefit from continuing immunotherapy based on the reported median OS and hazard ratios.
• Identify patient subgroups most likely to benefit from continued immunotherapy based on features like PD-L1 expression and first-line therapy response mentioned in the results.
• Evaluate the safety profile of continuing immunotherapy beyond progression compared to switching therapies.

Strengths

• Includes data from 169 patients, providing a substantial real-world cohort.
• Reports specific clinical outcomes including median PFS (4.4 vs. 3.0 months) and median OS (9.5 vs. 6.4 months) with hazard ratios and confidence intervals.
• Analysis includes multivariable adjustment and propensity score matching to control for confounding factors.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data may reflect single-center bias inherent to the study design.

Provenance

Source

Guangxi Wang

Collection Method

Single-center, retrospective study.

Freshness

Last updated 2026-06-03 04:47:38; freshness should be verified.